XML 29 R19.htm IDEA: XBRL DOCUMENT v3.25.2

Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2025

Accounting Policies [Abstract]

Percentage of Net Product Sales and Accounts Receivable Balance

The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:

		Net Product Sales								Accounts Receivable
		Three Months Ended June 30, 2025				Six Months Ended June 30, 2025				As of June 30, 2025
Customer A			44.2	%			43.9	%			43.8	%
Customer B			33.9	%			33.5	%			34.4	%
Customer C			20.4	%			21.2	%			21.3	%
Total			98.5	%			98.6	%			99.5	%

Schedule of Disaggregated Net Product Sales

The following table provides disaggregated net product sales (in thousands):

		Three Months Ended June 30,								Six Months Ended June 30,
		2025				2024				2025				2024
CINVANTI net product sales		$	24,143			$	24,927			$	49,886			$	50,544
SUSTOL net product sales			2,404				4,246				5,263				7,860
ZYNRELEF net product sales			8,189				5,831				16,230				10,844
APONVIE net product sales			2,464				1,020				4,724				1,446
Total net product sales		$	37,200			$	36,024			$	76,103			$	70,694

Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):

		Product Returns				Distributor Fees				Discounts, Rebates and Administrative Fees				Total
Balance at December 31, 2024		$	3,791			$	5,883			$	27,745			$	37,419
Provision			962				17,188				114,605				132,755
Payments/credits			(472	)			(17,028	)			(112,621	)			(130,121	)
Balance at June 30, 2025		$	4,281			$	6,043			$	29,729			$	40,053

Schedule of Numerator (Earnings or Loss) and Denominator (Weighted-Average Number of Common Shares Outstanding for Period, Including Pre-funded Warrants) to Calculate the Basic and Diluted Earnings Per Share

The computations of the numerator (earnings or loss) and denominator (weighted-average number of common shares outstanding for the period, including pre-funded warrants) to calculate the basic and diluted earnings per share amounts presented in the accompanying condensed consolidated statements of operations and comprehensive (loss) income are as follows (in thousands, except per share amounts):

		Three Months Ended June 30, 2025								Three Months Ended June 30, 2024								Six Months Ended June 30, 2025								Six Months Ended June 30, 2024
		Income				Shares				Income				Shares				Income				Shares				Income				Shares
Basic:
Net (loss) income		$	(2,381	)			154,020			$	(9,235	)			152,305			$	254				153,804			$	(12,395	)			151,900
(Loss) earnings per share, basic		$	(0.02	)						$	(0.06	)						$	0.00							$	(0.08	)
Diluted:
Net (loss) income		$	(2,381	)			154,020			$	(9,235	)			152,305			$	254				153,804			$	(12,395	)			151,900
Effect of dilutive securities:
Stock options outstanding			—				—				—				—				—				29,697				—				—
Restricted stock units outstanding			—				—				—				—				—				4,133				—				—
Warrants outstanding			—				—				—				—				—				298				—				—
Shares of common stock underlying convertible notes outstanding			—				—				—				—				—				9,819				—				—
Net (loss) income, diluted		$	(2,381	)			154,020			$	(9,235	)			152,305			$	254				197,751			$	(12,395	)			151,900
(Loss) earnings per share, diluted		$	(0.02	)						$	(0.06	)						$	0.00							$	(0.08	)

Common Stock Equivalents Excluded From Computation of Net Loss Per Share

Because we incurred a net loss for the three months ended June 30, 2025 and the three and six months ended June 30, 2024, the following common stock equivalents were not included in the computation of earnings per share because their effect would be anti-dilutive (in thousands):

		June 30,
		2025				2024
Stock options outstanding			29,697				27,445
Restricted stock units outstanding			4,133				1,642
Warrants outstanding			298				298
Shares of common stock underlying convertible notes outstanding			9,819				9,819

X

- Definition

Schedule of disaggregated net product sales.

+ References

No definition available.

+ Details

Name:	hrtx_ScheduleOfDisaggregatedNetProductSalesTableTextBlock
Namespace Prefix:	hrtx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.

+ References

No definition available.

+ Details

Name:	hrtx_ValuationAllowancesAndReservesTableTextBlock
Namespace Prefix:	hrtx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration